Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung

Jung J. Hung, Kuan Chih Chow, Hao W. Wang, Liang Shun Wang

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Background: The cytoplasmic enzyme dihydrodiol dehydrogenase (DDH) plays an important role in the detoxification process. Recently, the overexpression of DDH was detected in non-small cell lung cancer (NSCLC) cells and patients with DDH overexpression were shown to have a significantly higher incidence of early tumor recurrence and distant metastasis. In this study, the correlation between DDH expression and resistance to cisplatin, adriamycin and radiotherapy in NSCLC was examined. Materials and Methods: Seven lung adenocarcinoma cell lines (H23, H838, H1437, H1648, H2009, H2087 and H2126) were used in the study. The DDH level was determined by reverse transcription polymerase chain reaction and immunoblotting. Drug- and radiation-mediated cytotoxicity was measured by clonogenic assay. DDH isoforms (DDH1, DDH2 and DDH3) were transfected into H23 cells that did not express DDH to examine their effects on drug and radiation resistance. Results: DDH-overexpressed adenocarcinoma cells exhibited a much higher resistance to doxorubicin, cisplatin and irradiation than cells with lower DDH expression. The DDH2- and DDH1-transfectants showed higher drug and radiation resistance than the DDH3-trasnfectant. Conclusion: Resistance to both anticancer drugs and irradiation in lung adenocarcinoma cells was closely associated with DDH activity. DDH1 and DDH2 were the main isoforms responsible for these effects.

Original languageEnglish
Pages (from-to)2949-2955
Number of pages7
JournalAnticancer Research
Volume26
Issue number4 B
Publication statusPublished - Jul 2006
Externally publishedYes

Fingerprint

Radiotherapy
Drug Therapy
Radiation
Drug Resistance
Non-Small Cell Lung Carcinoma
Doxorubicin
Cisplatin
Protein Isoforms
Adenocarcinoma of lung
trans-1,2-dihydrobenzene-1,2-diol dehydrogenase
Immunoblotting
Pharmaceutical Preparations
Reverse Transcription
Adenocarcinoma
Neoplasm Metastasis
Recurrence
Cell Line
Polymerase Chain Reaction
Incidence
Enzymes

Keywords

  • Anticancer drug
  • Dihydrodiol dehydrogenase
  • Lung adenocarcinoma
  • Radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung. / Hung, Jung J.; Chow, Kuan Chih; Wang, Hao W.; Wang, Liang Shun.

In: Anticancer Research, Vol. 26, No. 4 B, 07.2006, p. 2949-2955.

Research output: Contribution to journalArticle

Hung, Jung J. ; Chow, Kuan Chih ; Wang, Hao W. ; Wang, Liang Shun. / Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung. In: Anticancer Research. 2006 ; Vol. 26, No. 4 B. pp. 2949-2955.
@article{df227117d67645299a7edfb9f1fe8738,
title = "Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung",
abstract = "Background: The cytoplasmic enzyme dihydrodiol dehydrogenase (DDH) plays an important role in the detoxification process. Recently, the overexpression of DDH was detected in non-small cell lung cancer (NSCLC) cells and patients with DDH overexpression were shown to have a significantly higher incidence of early tumor recurrence and distant metastasis. In this study, the correlation between DDH expression and resistance to cisplatin, adriamycin and radiotherapy in NSCLC was examined. Materials and Methods: Seven lung adenocarcinoma cell lines (H23, H838, H1437, H1648, H2009, H2087 and H2126) were used in the study. The DDH level was determined by reverse transcription polymerase chain reaction and immunoblotting. Drug- and radiation-mediated cytotoxicity was measured by clonogenic assay. DDH isoforms (DDH1, DDH2 and DDH3) were transfected into H23 cells that did not express DDH to examine their effects on drug and radiation resistance. Results: DDH-overexpressed adenocarcinoma cells exhibited a much higher resistance to doxorubicin, cisplatin and irradiation than cells with lower DDH expression. The DDH2- and DDH1-transfectants showed higher drug and radiation resistance than the DDH3-trasnfectant. Conclusion: Resistance to both anticancer drugs and irradiation in lung adenocarcinoma cells was closely associated with DDH activity. DDH1 and DDH2 were the main isoforms responsible for these effects.",
keywords = "Anticancer drug, Dihydrodiol dehydrogenase, Lung adenocarcinoma, Radiation",
author = "Hung, {Jung J.} and Chow, {Kuan Chih} and Wang, {Hao W.} and Wang, {Liang Shun}",
year = "2006",
month = "7",
language = "English",
volume = "26",
pages = "2949--2955",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "4 B",

}

TY - JOUR

T1 - Expression of dihydrodiol dehydrogenase and resistance to chemotherapy and radiotherapy in adenocarcinoma cells of lung

AU - Hung, Jung J.

AU - Chow, Kuan Chih

AU - Wang, Hao W.

AU - Wang, Liang Shun

PY - 2006/7

Y1 - 2006/7

N2 - Background: The cytoplasmic enzyme dihydrodiol dehydrogenase (DDH) plays an important role in the detoxification process. Recently, the overexpression of DDH was detected in non-small cell lung cancer (NSCLC) cells and patients with DDH overexpression were shown to have a significantly higher incidence of early tumor recurrence and distant metastasis. In this study, the correlation between DDH expression and resistance to cisplatin, adriamycin and radiotherapy in NSCLC was examined. Materials and Methods: Seven lung adenocarcinoma cell lines (H23, H838, H1437, H1648, H2009, H2087 and H2126) were used in the study. The DDH level was determined by reverse transcription polymerase chain reaction and immunoblotting. Drug- and radiation-mediated cytotoxicity was measured by clonogenic assay. DDH isoforms (DDH1, DDH2 and DDH3) were transfected into H23 cells that did not express DDH to examine their effects on drug and radiation resistance. Results: DDH-overexpressed adenocarcinoma cells exhibited a much higher resistance to doxorubicin, cisplatin and irradiation than cells with lower DDH expression. The DDH2- and DDH1-transfectants showed higher drug and radiation resistance than the DDH3-trasnfectant. Conclusion: Resistance to both anticancer drugs and irradiation in lung adenocarcinoma cells was closely associated with DDH activity. DDH1 and DDH2 were the main isoforms responsible for these effects.

AB - Background: The cytoplasmic enzyme dihydrodiol dehydrogenase (DDH) plays an important role in the detoxification process. Recently, the overexpression of DDH was detected in non-small cell lung cancer (NSCLC) cells and patients with DDH overexpression were shown to have a significantly higher incidence of early tumor recurrence and distant metastasis. In this study, the correlation between DDH expression and resistance to cisplatin, adriamycin and radiotherapy in NSCLC was examined. Materials and Methods: Seven lung adenocarcinoma cell lines (H23, H838, H1437, H1648, H2009, H2087 and H2126) were used in the study. The DDH level was determined by reverse transcription polymerase chain reaction and immunoblotting. Drug- and radiation-mediated cytotoxicity was measured by clonogenic assay. DDH isoforms (DDH1, DDH2 and DDH3) were transfected into H23 cells that did not express DDH to examine their effects on drug and radiation resistance. Results: DDH-overexpressed adenocarcinoma cells exhibited a much higher resistance to doxorubicin, cisplatin and irradiation than cells with lower DDH expression. The DDH2- and DDH1-transfectants showed higher drug and radiation resistance than the DDH3-trasnfectant. Conclusion: Resistance to both anticancer drugs and irradiation in lung adenocarcinoma cells was closely associated with DDH activity. DDH1 and DDH2 were the main isoforms responsible for these effects.

KW - Anticancer drug

KW - Dihydrodiol dehydrogenase

KW - Lung adenocarcinoma

KW - Radiation

UR - http://www.scopus.com/inward/record.url?scp=33746739480&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33746739480&partnerID=8YFLogxK

M3 - Article

C2 - 16886619

AN - SCOPUS:33746739480

VL - 26

SP - 2949

EP - 2955

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 4 B

ER -